Correspondence 0001213900-24-111070 from Park Ha Biological Technology Co., Ltd. (PHH) (CIK 0001986247) (BYAH)
Park Ha Biological Technology Co., Ltd. (PHH) (CIK 0001986247)
Date: Dec. 20, 2024 · CIK: 0001986247 · Accession: 0001213900-24-111070
AI Filing Summary & Sentiment
Letter
Re: Park Ha Biological Technology Co., Ltd.
VIA EDGAR
December 20, 2024
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, NE
Washington, D.C. 20549
Attn: Benjamin Richie
Registration Statement on Form F-1, as amended (File No. 333 - 281783)
Request For Acceleration of Effectiveness
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), Dawson James Securities Inc., acting as representative of the underwriters, hereby join Park Ha Biological Technology Co., Ltd in requesting acceleration of the effective date of the above-referenced Registration Statement so that it will become effective at 4:30 p.m., Eastern Time, on December 20, 2024, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Securities Act, we wish to advise you that we have distributed as many copies of the preliminary prospectus dated October 9, 2024, to selected dealers, institutions and others as appears to be reasonable to secure adequate distribution of the Preliminary Prospectus.
The undersigned confirm that it has complied and will continue to comply with, and it has been informed or will be informed by participating dealers that it has complied or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue.
Very truly yours,
Dawson James Securities Inc.
Show Raw Text
CORRESP
1
filename1.htm
VIA EDGAR
December 20, 2024
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, NE
Washington, D.C. 20549
Attn: Benjamin Richie
Re: Park Ha Biological Technology Co., Ltd.
Registration Statement on Form F-1, as amended
(File No. 333 - 281783)
Request For Acceleration of Effectiveness
Ladies and Gentlemen:
Pursuant to Rule 461 of the
General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities
Act”), Dawson James Securities Inc., acting as representative of the underwriters, hereby join Park Ha Biological Technology Co.,
Ltd in requesting acceleration of the effective date of the above-referenced Registration Statement so that it will become effective at
4:30 p.m., Eastern Time, on December 20, 2024, or as soon thereafter as practicable.
Pursuant to Rule 460 under
the Securities Act, we wish to advise you that we have distributed as many copies of the preliminary prospectus dated October 9, 2024,
to selected dealers, institutions and others as appears to be reasonable to secure adequate distribution of the Preliminary Prospectus.
The undersigned confirm that
it has complied and will continue to comply with, and it has been informed or will be informed by participating dealers that it has complied
or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced
issue.
Very truly yours,
Dawson James Securities Inc.
By:
/s/ Robert D. Keyser, Jr.
Name:
Robert D. Keyser, Jr.
Title:
Chief Executive Officer